Advertisement

Pharmaceutical Chemistry Journal

, Volume 48, Issue 3, pp 209–213 | Cite as

Solubilization of Hydrophobic Antitumor Drugs (Review)

  • I. D. Gulyakin
  • N. A. Oborotova
  • V. M. Pechennikov
DRUG SYNTHESIS METHODS AND MANUFACTURING TECHNOLOGY

Advances in chemotherapy always depend on the physician’s correct selection of a medicinal formulation in which the main active ingredient or complex of substances has the greatest therapeutic effect. From this point of view, the pharmacokinetics of injectable medicinal formulations are optimal in terms of achieving the required dose in the systemic circulation, as the bioavailability of an agent given intravenously reaches 100%. However, major problems in creating medicinal formulations are posed by medicinal substances with low solubility and the high lability of aqueous solutions of such substances. This review discusses the properties of current solubilizers used in the production of known hydrophobic antitumor formulations for parenteral use and in the development of new medicinal formulations of experimental compounds with cytotoxic effects and undergoing preclinical and clinical studies.

Keywords

injectable medicinal formulations solubilizers polyvinylpyrrolidone CremophorR EL dimethylsulfoxide 

References

  1. 1.
    N. A. Oborotova, Ros. Bioter. Zh., 2(2), 27 – 31 (2003).Google Scholar
  2. 2.
    G. A. Chernysheva, V. I. Smol’yakova, M. B. Plotnikov, et al., Khim.-Farm. Zh., 40(9), 7 – 8 (2006).Google Scholar
  3. 3.
    Z. S. Shprakh, N. A. Oborotova, L. I. Smirnova, et al., Khim.- Farm. Zh., 35(12), 42 – 47 (2001).Google Scholar
  4. 4.
    S. V. Glushen, S. V. Shlyakhtin, Yu. P. Istomin, et al., Tr. BGU Farmakol. Farmats., 5(1), 255 – 266 (2010).Google Scholar
  5. 5.
    N. A. Oborotova, B. S. Kikot’, A. P. Polozkova, et al., Khim.- Farm. Zh., 33(11), 53 – 56 (1999).Google Scholar
  6. 6.
    N. A. Oborotova, Z. S. Shprakh, B. L. Bagirova, et al., Khim.- Farm. Zh., 35(5), 39 – 43 (2001).Google Scholar
  7. 7.
    T. V. Kryuk, V. M. Mikhal’chuk, L. V. Petrenko, et al., Khim.- Farm. Zh., 36(1), 31 – 34 (2002).Google Scholar
  8. 8.
    V. I. Ivanova-Radkevich, L. V. Umnova, S. V. Barkanova, et al., Ros. Bioter. Zh., 7(3), 39 – 41 (2008).Google Scholar
  9. 9.
    Yu. N. Kukushkin, Sorosov. Obrazovat. Zh., 9, 54 – 59 (1997).Google Scholar
  10. 10.
    N. A. Grigorovich, Zdravookhran. Belorus., 3, 23 – 25 (1977).Google Scholar
  11. 11.
    L. B. Kalimullina, D 3191 – 78, All-Union Institute of Scientific Information and Technology (VINITI) (1978).Google Scholar
  12. 12.
    Z. S. Smirnova, I. Yu. Kubasova, L. M. Borisova, et al., Proceedings of the Scientific-Practical Conference “Russian Antitumor Agents,” Ros. Bioter. Zh., 5(1), (2006).Google Scholar
  13. 13.
    Experimental Oncology at the Turn of the Century [in Russian], M. I. Davydov and A. Yu. Baryshnikov (eds.), N. N. Blokhin Russian Oncological Scientific Center, Russian Academy of Medical Sciences Moscow (2003), pp. 31 – 43.Google Scholar
  14. 14.
    N. A. Oborotova, Z. S. Smirnova, A. P. Polozkova, and A. Yu. Baryshnikov, Vestn. Ros. Akad. Med. Nauk., No. 1, 42 – 45 (2002).Google Scholar
  15. 15.
    L. I. Smirnova, N. A. Oborotova, Z. S. Shprakh, et al., Vestn. RONTs RAMN, 4, 22 – 27 (2001).Google Scholar
  16. 16.
    N. A. Chikineva, Z. S. Smirnova, O. L. Orlova, et al., Khim.- Farm. Zh., 35(8), 34 – 35 (2001).Google Scholar
  17. 17.
    N. A. Oborotova, N. E. Ryshkova, Z. S. Smirnova, et al., Khim.-Farm. Zh., 35(2), 46 – 48 (2001).Google Scholar
  18. 18.
    N. E. Ryshkova, N. A. Oborotova, Z. S. Shprakh, et al., Khim.- Farm. Zh., 34(9), 46 – 48 (2000).Google Scholar
  19. 19.
    N. A. Oborotova, Z. S. Smirnova, and P. V. Lopatin, Med. Ref. Zh., 9, 1489 (1982).Google Scholar
  20. 20.
    K. D. Kaplanov, L. S. Tregubova, S. V. Egorov, et al., Vestn. VolGMU, 33(1), 77 – 81 (2010).Google Scholar
  21. 21.
    F. Sh. Akhmetzyanov, I. V. Shaimardanov, R. M. Shaimardanova, et al., Onkourologiya, 4, 12 – 16 (2007).Google Scholar
  22. 22.
    A. M. Garin, A. Yu. Baryshnikov, Z. G. Kadagidze, et al., Ros. Bioter. Zh., 5(2), 98 – 104 (2006).Google Scholar
  23. 23.
    L. M. Tukhvatullina and E. Yu. Antropova, Probl. Reproduktsii, 5, 21 – 23 (2008).Google Scholar
  24. 24.
    P. A. Gervas, A. Yu. Dobrodeev, and M. V. Vasil’eva, Sib. Onkol. Zh., 1, 48 – 49 (2009).Google Scholar
  25. 25.
    A. V. Meshechkin, Sib. onkol. zh., 1, 132 – 134 (2009)Google Scholar
  26. 26.
    I. G. Rusakov, B. V. Bukharkin, A. M. Ataev, et al., Onkourologiya, 2, 62 – 67 (2008).Google Scholar
  27. 27.
    L. R. Lichinitser, Farmateka, 14, 2 (2003).Google Scholar
  28. 28.
    Handbook of Oncology [in Russian], Vidal’ Spetsialist, Astra-FarmServis, Moscow (2006).Google Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • I. D. Gulyakin
    • 1
  • N. A. Oborotova
    • 1
    • 2
  • V. M. Pechennikov
    • 2
  1. 1.N. N. Blokhin Russian Oncological Scientific Center, Russian Academy of Medical SciencesMoscowRussia
  2. 2.I. M. Sechenov First Moscow State Medical UniversityMoscowRussia

Personalised recommendations